Ms. Liselotte Hyveled currently serves as the Chief Patient Officer at Novo Nordisk and is also a Board Director. Her tenure at Novo Nordisk spans more than 30 years and includes numerous leadership roles in strategy, clinical operations and R&D. Most recently, Ms. Hyveled was Principal Vice President, Strategy and Alliances, where she fostered relationships with public, private and academic institutions focused on drug development. Prior to that, she was Project Vice President, R&D, where she spearheaded and led drug development of assets from first human dose to market and clinical development projects. Previously, she held VP roles in trial execution and clinical operations. Beyond the clinic, she has lead CSR (corporate social responsibility) initiatives with a focus on neurodiversity, disabilities and generational intelligence.
Beyond her professional realm, Ms. Hyveled champions causes close to her heart, notably in the domains of neurodiversity, disabilities, and generational intelligence. Her commitment to social responsibility is palpable through her extensive record of community service and activism. Notably, she served as chairwoman of the Danish Disability Council, advocating ardently for the rights of individuals with disabilities.
Ms. Hyveled holds a Master of Pharmacy Science from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School.
